KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenon Pharmaceuticals (XENE) Operating Margin: 2013-2025

Historic Operating Margin for Xenon Pharmaceuticals (XENE) over the last 9 years, with Mar 2025 value amounting to -969.84%.

  • Xenon Pharmaceuticals' Operating Margin was N/A to -969.84% in Q1 2025 from the same period last year, while for Mar 2025 it was -1,730.22%, marking a year-over-year change of. This contributed to the annual value of -1,368.91% for FY2022, which is 94046.00% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Operating Margin of -969.84% as of Q1 2025, which was up 96.64% from -28,884.85% recorded in Q3 2022.
  • In the past 5 years, Xenon Pharmaceuticals' Operating Margin registered a high of -198.14% during Q1 2022, and its lowest value of -28,884.85% during Q3 2022.
  • For the 1-year period, Xenon Pharmaceuticals' Operating Margin averaged around -969.84%, with its median value being -969.84% (2025).
  • The largest annual percentage gain for Xenon Pharmaceuticals' Operating Margin in the last 5 years was 17,035bps (2022), contrasted with its biggest fall of 2,853,823bps (2022).
  • Over the past 3 years, Xenon Pharmaceuticals' Operating Margin (Quarterly) stood at -664.65% in 2021, then tumbled by 2,853,823bps to -28,884.85% in 2022, then reached -969.84% in 2025.
  • Its Operating Margin was -969.84% in Q1 2025, compared to -28,884.85% in Q3 2022 and -5,655.78% in Q2 2022.